Capstone Therapeutics Corp. (NASDAQ:CAPS) Short Interest Down 45.4% in April

Capstone Therapeutics Corp. (NASDAQ:CAPS) was the recipient of a large decrease in short interest in the month of April. As of April 15th, there was short interest totaling 73,622 shares, a decrease of 45.4% from the March 31st total of 134,793 shares. Approximately 1.6% of the company’s stock are sold short. Based on an average trading volume of 138,789 shares, the days-to-cover ratio is presently 0.5 days.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Capstone Therapeutics stock. DRW Securities LLC bought a new position in shares of Capstone Therapeutics Corp. (NASDAQ:CAPS) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm bought 125,422 shares of the company’s stock, valued at approximately $91,000. DRW Securities LLC owned about 1.51% of Capstone Therapeutics as of its most recent SEC filing. 2.55% of the stock is owned by institutional investors and hedge funds.

Capstone Therapeutics Stock Down 1.9%

CAPS stock traded down $0.01 during mid-day trading on Monday, hitting $0.42. 267,412 shares of the company were exchanged, compared to its average volume of 1,605,401. The company has a market capitalization of $4.76 million, a PE ratio of -0.11 and a beta of -1.27. The firm has a fifty day simple moving average of $0.60 and a 200 day simple moving average of $0.75. The company has a current ratio of 1.00, a quick ratio of 0.26 and a debt-to-equity ratio of 0.75. Capstone Therapeutics has a twelve month low of $0.36 and a twelve month high of $3.29.

Analysts Set New Price Targets

Separately, Weiss Ratings cut shares of Capstone Therapeutics from a “sell (e+)” rating to a “sell (e)” rating in a research report on Tuesday, April 21st. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, Capstone Therapeutics presently has an average rating of “Sell”.

About Capstone Therapeutics

Capstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona.